Nabi-Afjadi M, Mohebi F, Zalpoor H, Aziziyan F, Akbari A, Moradi-Sardareh H et al. A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? Inflammopharmacology. 2023:1–15.
Samidoust P, Delshad ME, Talemi RN, Mojtahedi K, Samidoust A, Jahangiri S et al. Incidence, characteristics, and outcome of COVID-19 in patients on liver transplant program: a retrospective study in the north of Iran. New Microbes New Infect. 2021;44:100935.
Aghajanzadeh M, Haghighi M, Rimaz S, Fomani AA, Tangestaninejad A, Ashoobi MT, et al. Pneumomediastinum, pneumopericardium pneumothorax and subcutaneous emphysema in iranian COVID-19 patients. J Curr Biomedical Rep. 2021;2(4):201–5.
Zalpoor H, Akbari A, Nabi-Afjadi M, Forghaniesfidvajani R, Tavakol C, Barzegar Z et al. Hypoxia-inducible factor 1 alpha (HIF‐1α) stimulated and P2X7 receptor activated by COVID-19, as a potential therapeutic target and risk factor for epilepsy. Human Cell. 2022:1–8.
Zalpoor H, Akbari A, Samei A, Forghaniesfidvajani R, Kamali M, Afzalnia A, et al. The roles of eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies. Cell Mol Biol Lett. 2022;27(1):1–21.
Zalpoor H, Akbari A, Nabi-Afjadi M. Ephrin (Eph) receptor and downstream signaling pathways: a promising potential targeted therapy for COVID–19 and associated cancers and diseases.Human Cell. 2022:1–3.
Wang K, Chen W, Zhang Z, Deng Y, Lian J-Q, Du P, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target therapy. 2020;5(1):1–10.
Beaudoin CA, Jamasb AR, Alsulami AF, Copoiu L, van Tonder AJ, Hala S, et al. Predicted structural mimicry of spike receptor-binding motifs from highly pathogenic human coronaviruses. Comput Struct Biotechnol J. 2021;19:3938–53.
Article CAS PubMed PubMed Central Google Scholar
Zalpoor H, Liaghat M, Bakhtiyari M, Shapourian H, Akbari A, Shahveh S, et al. Kaempferol’s potential effects against SARS-CoV-2 and COVID-19-associated cancer progression and chemo-resistance. Phytotherapy research: PTR; 2023.
Zalpoor H, Bakhtiyari M, Liaghat M, Nabi-Afjadi M, Ganjalikhani‐Hakemi M. Quercetin potential effects against SARS‐CoV‐2 infection and COVID‐19‐associated cancer progression by inhibiting mTOR and hypoxia‐inducible factor‐1α (HIF‐1α).Phytotherapy Research. 2022.
Zalpoor H, Bakhtiyari M, Shapourian H, Rostampour P, Tavakol C, Nabi-Afjadi M. Hesperetin as an anti-SARS-CoV-2 agent can inhibit COVID-19-associated cancer progression by suppressing intracellular signaling pathways.Inflammopharmacology. 2022:1–7.
Zalpoor H, Shapourian H, Akbari A, Shahveh S, Haghshenas L. Increased neuropilin-1 expression by COVID-19: a possible cause of long-term neurological complications and progression of primary brain tumors.Human Cell. 2022:1–3.
Zalpoor H, Rezaei M, Yahyazadeh S, Ganjalikhani-Hakemi M. Flt3-ITD mutated acute myeloid leukemia patients and COVID-19: potential roles of autophagy and HIF-1α in leukemia progression and mortality.Human Cell. 2022:1–2.
Zalpoor H, Akbari A, Nayerain Jazi N, Liaghat M, Bakhtiyari M. Possible role of autophagy induced by COVID-19 in cancer progression, chemo-resistance, and tumor recurrence. Infect Agents Cancer. 2022;17(1):1–4.
Liu C, von Brunn A, Zhu D, Cyclophilin. A and CD147: novel therapeutic targets for the treatment of COVID-19. Med drug discovery. 2020;7:100056.
Geng J, Chen L, Yuan Y, Wang K, Wang Y, Qin C, et al. CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. Sig Transduct Target Ther. 2021;6(1):1–13.
Zhang H, Chen J, Liu F, Gao C, Wang X, Zhao T, et al. CypA, a gene downstream of HIF-1α, promotes the development of PDAC. PLoS ONE. 2014;9(3):e92824.
Article PubMed PubMed Central Google Scholar
Lian C, Guo Y, Zhang J, Chen X, Peng C. Targeting CD147 is a novel strategy for antitumor therapy. Curr Pharm Design. 2017;23(29):4410–21.
Chen I-Y, Moriyama M, Chang M-F, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol. 2019;10:50.
Article PubMed PubMed Central Google Scholar
Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355–62.
Article CAS PubMed PubMed Central Google Scholar
Xin X, Zeng X, Gu H, Li M, Tan H, Jin Z, et al. CD147/EMMPRIN overexpression and prognosis in cancer: a systematic review and meta-analysis. Sci Rep. 2016;6(1):1–12.
Obchoei S, Weakley SM, Wongkham S, Wongkham C, Sawanyawisuth K, Yao Q, et al. Cyclophilin a enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma. Mol Cancer. 2011;10(1):1–15.
Cui H-Y, Wang S-J, Song F, Cheng X, Nan G, Zhao Y, et al. CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression. Sig Transduct Target Ther. 2021;6(1):1–15.
Cui H-Y, Wang S-J, Miao J-Y, Fu Z-G, Feng F, Wu J, et al. CD147 regulates cancer migration via direct interaction with annexin A2 and DOCK3-β-catenin-WAVE2 signaling. Oncotarget. 2016;7(5):5613.
Gao L, Nie X, Gou R, Qi Y, Liu J, Lin B. Interaction of CD147 and human epididymis protein 4 promotes invasion and metastasis of ovarian cancer. J Cancer. 2021;12(24):7422.
Article CAS PubMed PubMed Central Google Scholar
Dai L, Guinea MC, Slomiany MG, Bratoeva M, Grass GD, Tolliver LB, et al. CD147-dependent heterogeneity in malignant and chemoresistant properties of cancer cells. Am J Pathol. 2013;182(2):577–85.
Article CAS PubMed PubMed Central Google Scholar
Nan G, Zhao S-H, Wang T, Chao D, Tian R-F, Wang W-J et al. CD147 supports paclitaxel resistance via interacting with RanBP1.Oncogene. 2022:1–14.
Bu X, Qu X, Guo K, Meng X, Yang X, Huang Q, et al. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway. Int J Biol Sci. 2021;17(12):3013.
Article CAS PubMed PubMed Central Google Scholar
Gao J, Hu Z, Liu J, Liu D, Wang Y, Cai M, et al. Expression of CD147 and Lewis y antigen in ovarian cancer and their relationship to drug resistance. Med Oncol. 2014;31(5):1–8.
Peng L, Jiang J, Chen H-N, Zhou L, Huang Z, Qin S, et al. Redox-sensitive cyclophilin a elicits chemoresistance through realigning cellular oxidative status in colorectal cancer. Cell Rep. 2021;37(9):110069.
留言 (0)